Cargando…

Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma

The expression of programmed cell death ligand 1 (PD‐L1) is a biomarker for immunotherapy, but approved detection method is absent in diffuse large B‐cell lymphoma (DLBCL). Here, we performed three methods including immunohistochemistry (IHC) (clone SP263 and SP142), RNAscope, and fluorescence in si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Sixia, Nong, Lin, Liang, Li, Zheng, Yalin, Wang, Wei, Liu, Jumei, Li, Dong, Li, Xin, Wang, Ying, Zhang, Bo, Li, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639200/ https://www.ncbi.nlm.nih.gov/pubmed/31150165 http://dx.doi.org/10.1002/cam4.2316

Ejemplares similares

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T-cell lymphoma, nasal type
por: Liu, Jumei, et al.
Publicado: (2019)

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
por: Gu, Qianhui, et al.
Publicado: (2021)

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients
por: Hu, Maogui, et al.
Publicado: (2021)

Prediction of survival of diffuse large B‐cell lymphoma patients via the expression of three inflammatory genes
por: Zhao, Shuangtao, et al.
Publicado: (2016)

Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells
por: Ishikawa, Eri, et al.
Publicado: (2018)

Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B‐cell lymphoma
por: Tian, Tian, et al.
Publicado: (2020)

OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B‐cell lymphoma
por: Dong, Huan, et al.
Publicado: (2020)

Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
por: Weber, Manuel, et al.
Publicado: (2019)

Prostasin regulates PD-L1 expression in human lung cancer cells
por: Chen, Li-Mei, et al.
Publicado: (2021)

Exosomal PD‑L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B‑cell lymphoma
por: Zeng, Hui, et al.
Publicado: (2023)

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
por: Li, Xiao-Song, et al.
Publicado: (2020)

PD‐1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B‐cell lymphoma
por: Zhang, Wei, et al.
Publicado: (2016)

Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B‐cell lymphoma
por: Ma, Xiao‐bo, et al.
Publicado: (2018)

MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma
por: Kwanhian, Wiyada, et al.
Publicado: (2012)

Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful
por: Shah, Hina J., et al.
Publicado: (2017)

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
por: Fei, Yue, et al.
Publicado: (2020)

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway
por: Hu, Tonglin, et al.
Publicado: (2020)

The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis
por: Qiu, Liping, et al.
Publicado: (2019)

miR‐155‐regulated mTOR and Toll‐like receptor 5 in gastric diffuse large B‐cell lymphoma
por: Huang, Wei‐Ting, et al.
Publicado: (2021)

The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis
por: Wang, Bi‐Cheng, et al.
Publicado: (2019)

PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies
por: Ding, Lei, et al.
Publicado: (2021)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
por: Wu, Xuemei, et al.
Publicado: (2023)

Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma
por: Yan, Shufang, et al.
Publicado: (2022)

Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B‐cell lymphoma
por: Li, Xiaoqian, et al.
Publicado: (2019)

The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
por: Garcia-Lacarte, Marcos, et al.
Publicado: (2021)

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis
por: Liu, Pan‐pan, et al.
Publicado: (2018)

Surgery shows survival benefit in patients with primary intestinal diffuse large B‐cell lymphoma: A population‐based study
por: Wang, Moran, et al.
Publicado: (2021)

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
por: Huang, Yafang, et al.
Publicado: (2019)

The prognostic significance of monoclonal immunoglobulin gene rearrangement in conjunction with histologic B‐cell aggregates in the bone marrow of patients with diffuse large B‐cell lymphoma
por: Cho, Yoon Ah, et al.
Publicado: (2016)

The impact of structural factors on diagnostic delay in diffuse large B‐cell lymphoma
por: Zurko, Joanna C., et al.
Publicado: (2019)

Induction of autophagy and autophagy‐dependent apoptosis in diffuse large B‐cell lymphoma by a new antimalarial artemisinin derivative, SM1044
por: Cheng, Chunyan, et al.
Publicado: (2017)

PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis
por: Qin, Yuan, et al.
Publicado: (2021)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
por: Wang, Zhengyi, et al.
Publicado: (2020)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Associations between race and survival in pediatric patients with diffuse large B‐cell lymphoma
por: Khullar, Karishma, et al.
Publicado: (2021)

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy
por: Suzuki, Yuka, et al.
Publicado: (2020)

Mutational characteristics of gastrointestinal stromal tumors: A single-center analysis of 302 patients
por: Liang, Li, et al.
Publicado: (2021)

Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer
por: Steiniche, Torben, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_766nh9rurh0grr1t87t7vats9u